Aktienanalyse zu Trinity Biotech PLC (TRIB)TRIBTrinity Biotech PLC

Trinity Biotech plc is a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors. The Company develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market. The products are used to detect infectious diseases and to quantify the level of Hemoglobin A1c and other chemical parameters in serum, plasma and whole blood, and the Company intends to develop a range of biosensor devices and related services, starting with a continuous glucose monitoring product. Its TrinScreen Human Immunodeficiency Virus (HIV) rapid point-of-care test is a high-quality, single-use immunoassays to aid in the diagnosis of HIV. The Uni-Gold range of rapid point-of-care test devices consist of high-quality, single-use immunoassays to aid in the diagnosis of HIV. It operates in the Healthcare sector.

Trinity Biotech PLC (TRIB) is not a good buy right now due to its declining performance and negative financial indicators. The current price is $9.68, with a year-to-date change of -56.76%. The company has a forward P/E ratio of 4.54, which may seem attractive, but the gross margin has fluctuated significantly, with the latest at 35.21%. Furthermore, the RSI is at 31.19, indicating oversold conditions, but this could also suggest continued downward pressure. The main risk is the net income, which has been consistently negative, with the latest quarterly net income at -$17.48 million, highlighting ongoing financial struggles.

3 analysts cover TRIB: 3 rate it Buy, 0 Hold and 0 Sell.